title: Phase II study of high-dose epirubicin in non-small cell lung cancer.
abstract: 24 patients with measurable advanced non-small cell lung cancer (NSCLC) were treated with epirubicin 135-150 mg/m2 every 3 weeks. There were 6 partial responses. Randomised studies should reveal whether and how incorporation of epirubicin into combination chemotherapy can enhance outcome in advanced NSCLC.
authors.affiliation: Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Wils
authors.forename: I
authors.initials: I
authors.lastname: Utama
authors.forename: L
authors.initials: L
authors.lastname: Sala
authors.forename: J
authors.initials: J
authors.lastname: Smeets
authors.forename: A
authors.initials: A
authors.lastname: Riva
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D015251:Epirubicin